In glioblastoma patients receiving EGFR TKI targeted therapy, tumor cells acquire EGFR TKI resistance by eliminating EGFRvIII ecDNA, and EGFRvIII ecDNA reappear after drug withdrawal (90). This evidence concerns the gene EGFR and neoplasm.